Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
3,265
archived clinical trials in
Crohns Disease

Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)
Safety and Effectiveness of Live Zoster Vaccine in Anti-TNF Users (VERVE Trial)
Status: Enrolling
Updated:  12/31/1969
Southwest Rheumatology Research LLC
mi
from
Mesquite, TX
Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)
Safety and Effectiveness of Live Zoster Vaccine in Anti-TNF Users (VERVE Trial)
Status: Enrolling
Updated: 12/31/1969
Southwest Rheumatology Research LLC
mi
from
Mesquite, TX
Click here to add this to my saved trials
Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)
Safety and Effectiveness of Live Zoster Vaccine in Anti-TNF Users (VERVE Trial)
Status: Enrolling
Updated:  12/31/1969
University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)
Safety and Effectiveness of Live Zoster Vaccine in Anti-TNF Users (VERVE Trial)
Status: Enrolling
Updated: 12/31/1969
University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
Click here to add this to my saved trials
Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)
Safety and Effectiveness of Live Zoster Vaccine in Anti-TNF Users (VERVE Trial)
Status: Enrolling
Updated:  12/31/1969
West Virginia Research Institute
mi
from
South Charleston, WV
Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)
Safety and Effectiveness of Live Zoster Vaccine in Anti-TNF Users (VERVE Trial)
Status: Enrolling
Updated: 12/31/1969
West Virginia Research Institute
mi
from
South Charleston, WV
Click here to add this to my saved trials
A Long Term Extension Trial of BI 655066/ABBV-066 (Risankizumab) in Patients With Moderately to Severely Active Crohn's Disease
An Open Label, Single Group, Long Term Safety Extension Trial of BI 655066/ ABBV-066 (Risankizumab), in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
MGG Group, Inc.Chevy Chase Clinical Research /ID# 155068
mi
from
Chevy Chase, MD
A Long Term Extension Trial of BI 655066/ABBV-066 (Risankizumab) in Patients With Moderately to Severely Active Crohn's Disease
An Open Label, Single Group, Long Term Safety Extension Trial of BI 655066/ ABBV-066 (Risankizumab), in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
MGG Group, Inc.Chevy Chase Clinical Research /ID# 155068
mi
from
Chevy Chase, MD
Click here to add this to my saved trials
A Long Term Extension Trial of BI 655066/ABBV-066 (Risankizumab) in Patients With Moderately to Severely Active Crohn's Disease
An Open Label, Single Group, Long Term Safety Extension Trial of BI 655066/ ABBV-066 (Risankizumab), in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Clin Res Inst of Michigan, LLC /ID# 155066
mi
from
Chesterfield, MI
A Long Term Extension Trial of BI 655066/ABBV-066 (Risankizumab) in Patients With Moderately to Severely Active Crohn's Disease
An Open Label, Single Group, Long Term Safety Extension Trial of BI 655066/ ABBV-066 (Risankizumab), in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Clin Res Inst of Michigan, LLC /ID# 155066
mi
from
Chesterfield, MI
Click here to add this to my saved trials
A Long Term Extension Trial of BI 655066/ABBV-066 (Risankizumab) in Patients With Moderately to Severely Active Crohn's Disease
An Open Label, Single Group, Long Term Safety Extension Trial of BI 655066/ ABBV-066 (Risankizumab), in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Cliniques Universitaires Saint Luc /ID# 154985
mi
from
Woluwe-Saint-Lambert,
A Long Term Extension Trial of BI 655066/ABBV-066 (Risankizumab) in Patients With Moderately to Severely Active Crohn's Disease
An Open Label, Single Group, Long Term Safety Extension Trial of BI 655066/ ABBV-066 (Risankizumab), in Patients With Moderately to Severely Active Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Cliniques Universitaires Saint Luc /ID# 154985
mi
from
Woluwe-Saint-Lambert,
Click here to add this to my saved trials
Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease
A Phase 2, Multi-Center, Open-Label Induction Trial With Extension Period to Access Endoscopic Improvement and Changes in Intestinal and Serum Biomarkers in Patients With Moderately to Severely Active Crohn's Disease Receiving Oral RPC1063 as Induction Therapy
Status: Enrolling
Updated:  12/31/1969
Adobe Clinical Research, LLC
mi
from
Tucson, AZ
Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease
A Phase 2, Multi-Center, Open-Label Induction Trial With Extension Period to Access Endoscopic Improvement and Changes in Intestinal and Serum Biomarkers in Patients With Moderately to Severely Active Crohn's Disease Receiving Oral RPC1063 as Induction Therapy
Status: Enrolling
Updated: 12/31/1969
Adobe Clinical Research, LLC
mi
from
Tucson, AZ
Click here to add this to my saved trials
Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease
A Phase 2, Multi-Center, Open-Label Induction Trial With Extension Period to Access Endoscopic Improvement and Changes in Intestinal and Serum Biomarkers in Patients With Moderately to Severely Active Crohn's Disease Receiving Oral RPC1063 as Induction Therapy
Status: Enrolling
Updated:  12/31/1969
Florida Center for Gastroenterology
mi
from
Largo, FL
Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease
A Phase 2, Multi-Center, Open-Label Induction Trial With Extension Period to Access Endoscopic Improvement and Changes in Intestinal and Serum Biomarkers in Patients With Moderately to Severely Active Crohn's Disease Receiving Oral RPC1063 as Induction Therapy
Status: Enrolling
Updated: 12/31/1969
Florida Center for Gastroenterology
mi
from
Largo, FL
Click here to add this to my saved trials
Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease
A Phase 2, Multi-Center, Open-Label Induction Trial With Extension Period to Access Endoscopic Improvement and Changes in Intestinal and Serum Biomarkers in Patients With Moderately to Severely Active Crohn's Disease Receiving Oral RPC1063 as Induction Therapy
Status: Enrolling
Updated:  12/31/1969
IMIC
mi
from
Palmetto Bay, FL
Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease
A Phase 2, Multi-Center, Open-Label Induction Trial With Extension Period to Access Endoscopic Improvement and Changes in Intestinal and Serum Biomarkers in Patients With Moderately to Severely Active Crohn's Disease Receiving Oral RPC1063 as Induction Therapy
Status: Enrolling
Updated: 12/31/1969
IMIC
mi
from
Palmetto Bay, FL
Click here to add this to my saved trials
Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease
A Phase 2, Multi-Center, Open-Label Induction Trial With Extension Period to Access Endoscopic Improvement and Changes in Intestinal and Serum Biomarkers in Patients With Moderately to Severely Active Crohn's Disease Receiving Oral RPC1063 as Induction Therapy
Status: Enrolling
Updated:  12/31/1969
Atlanta Gastroenterology Specialists, PC
mi
from
Suwanee, GA
Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease
A Phase 2, Multi-Center, Open-Label Induction Trial With Extension Period to Access Endoscopic Improvement and Changes in Intestinal and Serum Biomarkers in Patients With Moderately to Severely Active Crohn's Disease Receiving Oral RPC1063 as Induction Therapy
Status: Enrolling
Updated: 12/31/1969
Atlanta Gastroenterology Specialists, PC
mi
from
Suwanee, GA
Click here to add this to my saved trials
Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease
A Phase 2, Multi-Center, Open-Label Induction Trial With Extension Period to Access Endoscopic Improvement and Changes in Intestinal and Serum Biomarkers in Patients With Moderately to Severely Active Crohn's Disease Receiving Oral RPC1063 as Induction Therapy
Status: Enrolling
Updated:  12/31/1969
DM Clinical Research
mi
from
Oak Lawn, IL
Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease
A Phase 2, Multi-Center, Open-Label Induction Trial With Extension Period to Access Endoscopic Improvement and Changes in Intestinal and Serum Biomarkers in Patients With Moderately to Severely Active Crohn's Disease Receiving Oral RPC1063 as Induction Therapy
Status: Enrolling
Updated: 12/31/1969
DM Clinical Research
mi
from
Oak Lawn, IL
Click here to add this to my saved trials
Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease
A Phase 2, Multi-Center, Open-Label Induction Trial With Extension Period to Access Endoscopic Improvement and Changes in Intestinal and Serum Biomarkers in Patients With Moderately to Severely Active Crohn's Disease Receiving Oral RPC1063 as Induction Therapy
Status: Enrolling
Updated:  12/31/1969
Gastroenterology Associates
mi
from
Baton Rouge, LA
Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease
A Phase 2, Multi-Center, Open-Label Induction Trial With Extension Period to Access Endoscopic Improvement and Changes in Intestinal and Serum Biomarkers in Patients With Moderately to Severely Active Crohn's Disease Receiving Oral RPC1063 as Induction Therapy
Status: Enrolling
Updated: 12/31/1969
Gastroenterology Associates
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease
A Phase 2, Multi-Center, Open-Label Induction Trial With Extension Period to Access Endoscopic Improvement and Changes in Intestinal and Serum Biomarkers in Patients With Moderately to Severely Active Crohn's Disease Receiving Oral RPC1063 as Induction Therapy
Status: Enrolling
Updated:  12/31/1969
Chevy Chase Clinical Research
mi
from
Chevy Chase, MD
Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease
A Phase 2, Multi-Center, Open-Label Induction Trial With Extension Period to Access Endoscopic Improvement and Changes in Intestinal and Serum Biomarkers in Patients With Moderately to Severely Active Crohn's Disease Receiving Oral RPC1063 as Induction Therapy
Status: Enrolling
Updated: 12/31/1969
Chevy Chase Clinical Research
mi
from
Chevy Chase, MD
Click here to add this to my saved trials
Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease
A Phase 2, Multi-Center, Open-Label Induction Trial With Extension Period to Access Endoscopic Improvement and Changes in Intestinal and Serum Biomarkers in Patients With Moderately to Severely Active Crohn's Disease Receiving Oral RPC1063 as Induction Therapy
Status: Enrolling
Updated:  12/31/1969
Ehrhardt Clinical Research, LLC
mi
from
Belton, MO
Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease
A Phase 2, Multi-Center, Open-Label Induction Trial With Extension Period to Access Endoscopic Improvement and Changes in Intestinal and Serum Biomarkers in Patients With Moderately to Severely Active Crohn's Disease Receiving Oral RPC1063 as Induction Therapy
Status: Enrolling
Updated: 12/31/1969
Ehrhardt Clinical Research, LLC
mi
from
Belton, MO
Click here to add this to my saved trials
Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease
A Phase 2, Multi-Center, Open-Label Induction Trial With Extension Period to Access Endoscopic Improvement and Changes in Intestinal and Serum Biomarkers in Patients With Moderately to Severely Active Crohn's Disease Receiving Oral RPC1063 as Induction Therapy
Status: Enrolling
Updated:  12/31/1969
UC Health Clinical Trials Office
mi
from
Cincinnati, OH
Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease
A Phase 2, Multi-Center, Open-Label Induction Trial With Extension Period to Access Endoscopic Improvement and Changes in Intestinal and Serum Biomarkers in Patients With Moderately to Severely Active Crohn's Disease Receiving Oral RPC1063 as Induction Therapy
Status: Enrolling
Updated: 12/31/1969
UC Health Clinical Trials Office
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease
A Phase 2, Multi-Center, Open-Label Induction Trial With Extension Period to Access Endoscopic Improvement and Changes in Intestinal and Serum Biomarkers in Patients With Moderately to Severely Active Crohn's Disease Receiving Oral RPC1063 as Induction Therapy
Status: Enrolling
Updated:  12/31/1969
Ohio State University Clinical Trials Management Office
mi
from
Columbus, OH
Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease
A Phase 2, Multi-Center, Open-Label Induction Trial With Extension Period to Access Endoscopic Improvement and Changes in Intestinal and Serum Biomarkers in Patients With Moderately to Severely Active Crohn's Disease Receiving Oral RPC1063 as Induction Therapy
Status: Enrolling
Updated: 12/31/1969
Ohio State University Clinical Trials Management Office
mi
from
Columbus, OH
Click here to add this to my saved trials
Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease
A Phase 2, Multi-Center, Open-Label Induction Trial With Extension Period to Access Endoscopic Improvement and Changes in Intestinal and Serum Biomarkers in Patients With Moderately to Severely Active Crohn's Disease Receiving Oral RPC1063 as Induction Therapy
Status: Enrolling
Updated:  12/31/1969
Gastroenterology Associates of Orangeburg, PA
mi
from
Orangeburg, SC
Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease
A Phase 2, Multi-Center, Open-Label Induction Trial With Extension Period to Access Endoscopic Improvement and Changes in Intestinal and Serum Biomarkers in Patients With Moderately to Severely Active Crohn's Disease Receiving Oral RPC1063 as Induction Therapy
Status: Enrolling
Updated: 12/31/1969
Gastroenterology Associates of Orangeburg, PA
mi
from
Orangeburg, SC
Click here to add this to my saved trials
Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease
A Phase 2, Multi-Center, Open-Label Induction Trial With Extension Period to Access Endoscopic Improvement and Changes in Intestinal and Serum Biomarkers in Patients With Moderately to Severely Active Crohn's Disease Receiving Oral RPC1063 as Induction Therapy
Status: Enrolling
Updated:  12/31/1969
Gastro One
mi
from
Germantown, TN
Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease
A Phase 2, Multi-Center, Open-Label Induction Trial With Extension Period to Access Endoscopic Improvement and Changes in Intestinal and Serum Biomarkers in Patients With Moderately to Severely Active Crohn's Disease Receiving Oral RPC1063 as Induction Therapy
Status: Enrolling
Updated: 12/31/1969
Gastro One
mi
from
Germantown, TN
Click here to add this to my saved trials
Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease
A Phase 2, Multi-Center, Open-Label Induction Trial With Extension Period to Access Endoscopic Improvement and Changes in Intestinal and Serum Biomarkers in Patients With Moderately to Severely Active Crohn's Disease Receiving Oral RPC1063 as Induction Therapy
Status: Enrolling
Updated:  12/31/1969
San Antonio Gastroenterology
mi
from
San Antonio, TX
Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease
A Phase 2, Multi-Center, Open-Label Induction Trial With Extension Period to Access Endoscopic Improvement and Changes in Intestinal and Serum Biomarkers in Patients With Moderately to Severely Active Crohn's Disease Receiving Oral RPC1063 as Induction Therapy
Status: Enrolling
Updated: 12/31/1969
San Antonio Gastroenterology
mi
from
San Antonio, TX
Click here to add this to my saved trials
Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease
A Phase 2, Multi-Center, Open-Label Induction Trial With Extension Period to Access Endoscopic Improvement and Changes in Intestinal and Serum Biomarkers in Patients With Moderately to Severely Active Crohn's Disease Receiving Oral RPC1063 as Induction Therapy
Status: Enrolling
Updated:  12/31/1969
LHSC - Victoria Hospital
mi
from
London,
Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease
A Phase 2, Multi-Center, Open-Label Induction Trial With Extension Period to Access Endoscopic Improvement and Changes in Intestinal and Serum Biomarkers in Patients With Moderately to Severely Active Crohn's Disease Receiving Oral RPC1063 as Induction Therapy
Status: Enrolling
Updated: 12/31/1969
LHSC - Victoria Hospital
mi
from
London,
Click here to add this to my saved trials
Impact of Medical Treatment on Sexual Function in Patients With Crohn's Disease
Impact of Medical Treatment on Sexual Function in Patients With Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Mercy Medical Center
mi
from
Baltimore, MD
Impact of Medical Treatment on Sexual Function in Patients With Crohn's Disease
Impact of Medical Treatment on Sexual Function in Patients With Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Mercy Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Impact of Medical Treatment on Sexual Function in Patients With Crohn's Disease
Impact of Medical Treatment on Sexual Function in Patients With Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Penn State Hershey Medical Center
mi
from
Hershey, PA
Impact of Medical Treatment on Sexual Function in Patients With Crohn's Disease
Impact of Medical Treatment on Sexual Function in Patients With Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Penn State Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Impact of Medical Treatment on Sexual Function in Patients With Crohn's Disease
Impact of Medical Treatment on Sexual Function in Patients With Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
Vanderbilt University
mi
from
Nashville, TN
Impact of Medical Treatment on Sexual Function in Patients With Crohn's Disease
Impact of Medical Treatment on Sexual Function in Patients With Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
Vanderbilt University
mi
from
Nashville, TN
Click here to add this to my saved trials
Impact of Medical Treatment on Sexual Function in Patients With Crohn's Disease
Impact of Medical Treatment on Sexual Function in Patients With Crohn's Disease
Status: Enrolling
Updated:  12/31/1969
University of Maryland School of Medicine
mi
from
Baltimore, MD
Impact of Medical Treatment on Sexual Function in Patients With Crohn's Disease
Impact of Medical Treatment on Sexual Function in Patients With Crohn's Disease
Status: Enrolling
Updated: 12/31/1969
University of Maryland School of Medicine
mi
from
Baltimore, MD
Click here to add this to my saved trials
Medication Adherence in Patients With Inflammatory Bowel Disease (IBD)
Assessment of Health Literacy, Medication Adherence, and a Pilot Multi-component Intervention to Improve Medication Adherence in Patients With Inflammatory Bowel Disease
Status: Enrolling
Updated:  12/31/1969
The Emory Clinic
mi
from
Atlanta, GA
Medication Adherence in Patients With Inflammatory Bowel Disease (IBD)
Assessment of Health Literacy, Medication Adherence, and a Pilot Multi-component Intervention to Improve Medication Adherence in Patients With Inflammatory Bowel Disease
Status: Enrolling
Updated: 12/31/1969
The Emory Clinic
mi
from
Atlanta, GA
Click here to add this to my saved trials
Volatiles in Exhaled Breath and Blood in Crohn's Disease: Validation Cohort
Volatiles in Exhaled Breath and Blood in Crohn's Disease: Validation Cohort
Status: Enrolling
Updated:  12/31/1969
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Volatiles in Exhaled Breath and Blood in Crohn's Disease: Validation Cohort
Volatiles in Exhaled Breath and Blood in Crohn's Disease: Validation Cohort
Status: Enrolling
Updated: 12/31/1969
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
Evaluation of Efficacy and Safety of MEDI2070 in Subjects With Active, Moderate to Severe Crohn's Disease
A Phase 2b Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects With Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti Tumor Necrosis Factor-Alpha Therapy
Status: Enrolling
Updated:  12/31/1969
Arizona Arthritis & Rheumatology Research PLLC
mi
from
Phoenix, AZ
Evaluation of Efficacy and Safety of MEDI2070 in Subjects With Active, Moderate to Severe Crohn's Disease
A Phase 2b Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects With Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti Tumor Necrosis Factor-Alpha Therapy
Status: Enrolling
Updated: 12/31/1969
Arizona Arthritis & Rheumatology Research PLLC
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Evaluation of Efficacy and Safety of MEDI2070 in Subjects With Active, Moderate to Severe Crohn's Disease
A Phase 2b Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects With Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti Tumor Necrosis Factor-Alpha Therapy
Status: Enrolling
Updated:  12/31/1969
South Denver Gastroenterology
mi
from
Lone Tree, CO
Evaluation of Efficacy and Safety of MEDI2070 in Subjects With Active, Moderate to Severe Crohn's Disease
A Phase 2b Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects With Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti Tumor Necrosis Factor-Alpha Therapy
Status: Enrolling
Updated: 12/31/1969
South Denver Gastroenterology
mi
from
Lone Tree, CO
Click here to add this to my saved trials
Evaluation of Efficacy and Safety of MEDI2070 in Subjects With Active, Moderate to Severe Crohn's Disease
A Phase 2b Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects With Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti Tumor Necrosis Factor-Alpha Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research of West Florida - Corporate
mi
from
Clearwater, FL
Evaluation of Efficacy and Safety of MEDI2070 in Subjects With Active, Moderate to Severe Crohn's Disease
A Phase 2b Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects With Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti Tumor Necrosis Factor-Alpha Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research of West Florida - Corporate
mi
from
Clearwater, FL
Click here to add this to my saved trials
Evaluation of Efficacy and Safety of MEDI2070 in Subjects With Active, Moderate to Severe Crohn's Disease
A Phase 2b Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects With Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti Tumor Necrosis Factor-Alpha Therapy
Status: Enrolling
Updated:  12/31/1969
Borland-Groover Clinic
mi
from
Jacksonville, FL
Evaluation of Efficacy and Safety of MEDI2070 in Subjects With Active, Moderate to Severe Crohn's Disease
A Phase 2b Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects With Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti Tumor Necrosis Factor-Alpha Therapy
Status: Enrolling
Updated: 12/31/1969
Borland-Groover Clinic
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Evaluation of Efficacy and Safety of MEDI2070 in Subjects With Active, Moderate to Severe Crohn's Disease
A Phase 2b Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects With Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti Tumor Necrosis Factor-Alpha Therapy
Status: Enrolling
Updated:  12/31/1969
Advanced Pharma CR, LLC
mi
from
Miami, FL
Evaluation of Efficacy and Safety of MEDI2070 in Subjects With Active, Moderate to Severe Crohn's Disease
A Phase 2b Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects With Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti Tumor Necrosis Factor-Alpha Therapy
Status: Enrolling
Updated: 12/31/1969
Advanced Pharma CR, LLC
mi
from
Miami, FL
Click here to add this to my saved trials
Evaluation of Efficacy and Safety of MEDI2070 in Subjects With Active, Moderate to Severe Crohn's Disease
A Phase 2b Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects With Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti Tumor Necrosis Factor-Alpha Therapy
Status: Enrolling
Updated:  12/31/1969
IMIC
mi
from
Palmetto Bay, FL
Evaluation of Efficacy and Safety of MEDI2070 in Subjects With Active, Moderate to Severe Crohn's Disease
A Phase 2b Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects With Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti Tumor Necrosis Factor-Alpha Therapy
Status: Enrolling
Updated: 12/31/1969
IMIC
mi
from
Palmetto Bay, FL
Click here to add this to my saved trials
Evaluation of Efficacy and Safety of MEDI2070 in Subjects With Active, Moderate to Severe Crohn's Disease
A Phase 2b Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects With Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti Tumor Necrosis Factor-Alpha Therapy
Status: Enrolling
Updated:  12/31/1969
University of Chicago Medical Center
mi
from
Chicago, IL
Evaluation of Efficacy and Safety of MEDI2070 in Subjects With Active, Moderate to Severe Crohn's Disease
A Phase 2b Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects With Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti Tumor Necrosis Factor-Alpha Therapy
Status: Enrolling
Updated: 12/31/1969
University of Chicago Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Evaluation of Efficacy and Safety of MEDI2070 in Subjects With Active, Moderate to Severe Crohn's Disease
A Phase 2b Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects With Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti Tumor Necrosis Factor-Alpha Therapy
Status: Enrolling
Updated:  12/31/1969
NorthShore University HealthSystem
mi
from
Evanston, IL
Evaluation of Efficacy and Safety of MEDI2070 in Subjects With Active, Moderate to Severe Crohn's Disease
A Phase 2b Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects With Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti Tumor Necrosis Factor-Alpha Therapy
Status: Enrolling
Updated: 12/31/1969
NorthShore University HealthSystem
mi
from
Evanston, IL
Click here to add this to my saved trials
Evaluation of Efficacy and Safety of MEDI2070 in Subjects With Active, Moderate to Severe Crohn's Disease
A Phase 2b Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects With Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti Tumor Necrosis Factor-Alpha Therapy
Status: Enrolling
Updated:  12/31/1969
Indiana University
mi
from
Indianapolis, IN
Evaluation of Efficacy and Safety of MEDI2070 in Subjects With Active, Moderate to Severe Crohn's Disease
A Phase 2b Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects With Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti Tumor Necrosis Factor-Alpha Therapy
Status: Enrolling
Updated: 12/31/1969
Indiana University
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Evaluation of Efficacy and Safety of MEDI2070 in Subjects With Active, Moderate to Severe Crohn's Disease
A Phase 2b Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects With Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti Tumor Necrosis Factor-Alpha Therapy
Status: Enrolling
Updated:  12/31/1969
Cotton-O'Neil Clinical Research Center, Digestive Health
mi
from
Topeka, KA
Evaluation of Efficacy and Safety of MEDI2070 in Subjects With Active, Moderate to Severe Crohn's Disease
A Phase 2b Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects With Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti Tumor Necrosis Factor-Alpha Therapy
Status: Enrolling
Updated: 12/31/1969
Cotton-O'Neil Clinical Research Center, Digestive Health
mi
from
Topeka, KA
Click here to add this to my saved trials
Evaluation of Efficacy and Safety of MEDI2070 in Subjects With Active, Moderate to Severe Crohn's Disease
A Phase 2b Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects With Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti Tumor Necrosis Factor-Alpha Therapy
Status: Enrolling
Updated:  12/31/1969
Graves-Gilbert Clinic
mi
from
Bowling Green, KY
Evaluation of Efficacy and Safety of MEDI2070 in Subjects With Active, Moderate to Severe Crohn's Disease
A Phase 2b Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects With Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti Tumor Necrosis Factor-Alpha Therapy
Status: Enrolling
Updated: 12/31/1969
Graves-Gilbert Clinic
mi
from
Bowling Green, KY
Click here to add this to my saved trials
Evaluation of Efficacy and Safety of MEDI2070 in Subjects With Active, Moderate to Severe Crohn's Disease
A Phase 2b Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects With Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti Tumor Necrosis Factor-Alpha Therapy
Status: Enrolling
Updated:  12/31/1969
University of Louisville
mi
from
Louisville, KY
Evaluation of Efficacy and Safety of MEDI2070 in Subjects With Active, Moderate to Severe Crohn's Disease
A Phase 2b Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects With Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti Tumor Necrosis Factor-Alpha Therapy
Status: Enrolling
Updated: 12/31/1969
University of Louisville
mi
from
Louisville, KY
Click here to add this to my saved trials
Evaluation of Efficacy and Safety of MEDI2070 in Subjects With Active, Moderate to Severe Crohn's Disease
A Phase 2b Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects With Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti Tumor Necrosis Factor-Alpha Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Trials of SW Louisiana LLC
mi
from
Lake Charles, LA
Evaluation of Efficacy and Safety of MEDI2070 in Subjects With Active, Moderate to Severe Crohn's Disease
A Phase 2b Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects With Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti Tumor Necrosis Factor-Alpha Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Trials of SW Louisiana LLC
mi
from
Lake Charles, LA
Click here to add this to my saved trials
Evaluation of Efficacy and Safety of MEDI2070 in Subjects With Active, Moderate to Severe Crohn's Disease
A Phase 2b Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects With Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti Tumor Necrosis Factor-Alpha Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Trials Management
mi
from
Metairie, LA
Evaluation of Efficacy and Safety of MEDI2070 in Subjects With Active, Moderate to Severe Crohn's Disease
A Phase 2b Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects With Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti Tumor Necrosis Factor-Alpha Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Trials Management
mi
from
Metairie, LA
Click here to add this to my saved trials
Evaluation of Efficacy and Safety of MEDI2070 in Subjects With Active, Moderate to Severe Crohn's Disease
A Phase 2b Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects With Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti Tumor Necrosis Factor-Alpha Therapy
Status: Enrolling
Updated:  12/31/1969
University of Michigan Health System
mi
from
Ann Arbor, MI
Evaluation of Efficacy and Safety of MEDI2070 in Subjects With Active, Moderate to Severe Crohn's Disease
A Phase 2b Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects With Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti Tumor Necrosis Factor-Alpha Therapy
Status: Enrolling
Updated: 12/31/1969
University of Michigan Health System
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Evaluation of Efficacy and Safety of MEDI2070 in Subjects With Active, Moderate to Severe Crohn's Disease
A Phase 2b Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects With Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti Tumor Necrosis Factor-Alpha Therapy
Status: Enrolling
Updated:  12/31/1969
Revive Research Institute
mi
from
Southfield, MI
Evaluation of Efficacy and Safety of MEDI2070 in Subjects With Active, Moderate to Severe Crohn's Disease
A Phase 2b Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects With Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti Tumor Necrosis Factor-Alpha Therapy
Status: Enrolling
Updated: 12/31/1969
Revive Research Institute
mi
from
Southfield, MI
Click here to add this to my saved trials
Evaluation of Efficacy and Safety of MEDI2070 in Subjects With Active, Moderate to Severe Crohn's Disease
A Phase 2b Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects With Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti Tumor Necrosis Factor-Alpha Therapy
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Rochester
mi
from
Rochester, MN
Evaluation of Efficacy and Safety of MEDI2070 in Subjects With Active, Moderate to Severe Crohn's Disease
A Phase 2b Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects With Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti Tumor Necrosis Factor-Alpha Therapy
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
Evaluation of Efficacy and Safety of MEDI2070 in Subjects With Active, Moderate to Severe Crohn's Disease
A Phase 2b Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects With Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti Tumor Necrosis Factor-Alpha Therapy
Status: Enrolling
Updated:  12/31/1969
Ehrhardt Clinical Research, LLC
mi
from
Belton, MO
Evaluation of Efficacy and Safety of MEDI2070 in Subjects With Active, Moderate to Severe Crohn's Disease
A Phase 2b Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects With Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti Tumor Necrosis Factor-Alpha Therapy
Status: Enrolling
Updated: 12/31/1969
Ehrhardt Clinical Research, LLC
mi
from
Belton, MO
Click here to add this to my saved trials
Evaluation of Efficacy and Safety of MEDI2070 in Subjects With Active, Moderate to Severe Crohn's Disease
A Phase 2b Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects With Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti Tumor Necrosis Factor-Alpha Therapy
Status: Enrolling
Updated:  12/31/1969
New York University Medical Center
mi
from
Great Neck, NY
Evaluation of Efficacy and Safety of MEDI2070 in Subjects With Active, Moderate to Severe Crohn's Disease
A Phase 2b Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects With Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti Tumor Necrosis Factor-Alpha Therapy
Status: Enrolling
Updated: 12/31/1969
New York University Medical Center
mi
from
Great Neck, NY
Click here to add this to my saved trials
Evaluation of Efficacy and Safety of MEDI2070 in Subjects With Active, Moderate to Severe Crohn's Disease
A Phase 2b Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects With Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti Tumor Necrosis Factor-Alpha Therapy
Status: Enrolling
Updated:  12/31/1969
Premier Medical Group of the Hudson Valley
mi
from
Poughkeepsie, NY
Evaluation of Efficacy and Safety of MEDI2070 in Subjects With Active, Moderate to Severe Crohn's Disease
A Phase 2b Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects With Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti Tumor Necrosis Factor-Alpha Therapy
Status: Enrolling
Updated: 12/31/1969
Premier Medical Group of the Hudson Valley
mi
from
Poughkeepsie, NY
Click here to add this to my saved trials
Evaluation of Efficacy and Safety of MEDI2070 in Subjects With Active, Moderate to Severe Crohn's Disease
A Phase 2b Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects With Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti Tumor Necrosis Factor-Alpha Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Inquest Center, Ltd.
mi
from
Dayton, OH
Evaluation of Efficacy and Safety of MEDI2070 in Subjects With Active, Moderate to Severe Crohn's Disease
A Phase 2b Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects With Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti Tumor Necrosis Factor-Alpha Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Inquest Center, Ltd.
mi
from
Dayton, OH
Click here to add this to my saved trials
Evaluation of Efficacy and Safety of MEDI2070 in Subjects With Active, Moderate to Severe Crohn's Disease
A Phase 2b Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects With Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti Tumor Necrosis Factor-Alpha Therapy
Status: Enrolling
Updated:  12/31/1969
Donald Guthrie Foundation
mi
from
Sayre, PA
Evaluation of Efficacy and Safety of MEDI2070 in Subjects With Active, Moderate to Severe Crohn's Disease
A Phase 2b Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects With Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti Tumor Necrosis Factor-Alpha Therapy
Status: Enrolling
Updated: 12/31/1969
Donald Guthrie Foundation
mi
from
Sayre, PA
Click here to add this to my saved trials
Evaluation of Efficacy and Safety of MEDI2070 in Subjects With Active, Moderate to Severe Crohn's Disease
A Phase 2b Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects With Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti Tumor Necrosis Factor-Alpha Therapy
Status: Enrolling
Updated:  12/31/1969
Erlanger Health System
mi
from
Chattanooga, TN
Evaluation of Efficacy and Safety of MEDI2070 in Subjects With Active, Moderate to Severe Crohn's Disease
A Phase 2b Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects With Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti Tumor Necrosis Factor-Alpha Therapy
Status: Enrolling
Updated: 12/31/1969
Erlanger Health System
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Evaluation of Efficacy and Safety of MEDI2070 in Subjects With Active, Moderate to Severe Crohn's Disease
A Phase 2b Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects With Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti Tumor Necrosis Factor-Alpha Therapy
Status: Enrolling
Updated:  12/31/1969
University of Texas Health Science Center at Houston
mi
from
Houston, TX
Evaluation of Efficacy and Safety of MEDI2070 in Subjects With Active, Moderate to Severe Crohn's Disease
A Phase 2b Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects With Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti Tumor Necrosis Factor-Alpha Therapy
Status: Enrolling
Updated: 12/31/1969
University of Texas Health Science Center at Houston
mi
from
Houston, TX
Click here to add this to my saved trials